TrialBlood2026

NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.

Keiji Nogami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.